NCT01014416View on ClinicalTrials.gov

Pharmacokinetics/Pharmacodynamics (PK/PD) Characteristics of Tolvaptan Tablet in Korean Healthy Male

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Healthy
Interventions
DRUG

Tolvaptan 15mg or 30mg or 60mg or Placebo

Single dose of Tolvaptan 15mg or 30mg or 60mg or Placebo per day

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Korea Otsuka Pharmaceutical Co., Ltd.

INDUSTRY